Skip to main content

Table 4 Outcome data

From: Coronary artery bypass graft surgery in patients on ticagrelor therapy is not associated with adverse perioperative outcomes

 

Group A

ASA alone

%(n = 106)

Group B

Ticagrelor +ASA

%(n = 55)

p-Value

Time in intensive care unit (hrs)

93 ± 70

70 ± 24

0.005

Ventilation time (hrs)

13 ± 13

15 ± 16

0.990

Intraaortic balloon pump (%, n)

2 (2)

4 (2)

0.608

Post operative discharge day

8.3 ± 8.1

7.3 ± 4.6

0.552

Lowest Hemoglobin (gr/dl)

8.6 ± 1.2

8.4 ± 0.9

0.028

Δ Hemoglobin (gr/dl)

2.7 ± 1.3

2.5 ± 1.3

0.804

Chest drainage volume (ml)

 Day 1

569 ± 393

649 ± 427

0.854

 Total volume

1477 ± 1012

1454 ± 715

0.086

Blood products infused (units)

 Red blood packed cells

1.2 ± 1.6

1.3 ± 1.3

0.576

 Fresh frozen plasma

0.5 ± 1.2

0.4 ± 1

0.112

 Cryoprecipitate

0.2 ± 1.4

0.1 ± 0.8

0.420

 Platelets

2.3 ± 3.8

2.4 ± 3.4

0.547

Complications (n,%)

 Bleeding requiring surgical re-exploration

0

0

NS

 Neurologic (incl. stroke)

1 (1)

0 (0)

NS

 Pneumonia

4 (4)

5 (3)

0.692

 Infection (any)

5 (5)

10 (5)

0.316

 Renal failure

10 (10)

2 (1)

0.099

  Requiring dialysis

0

0

NS

  Discharged with dialysis

0

0

NS

 Atrial fibrillation

38 (40)

22 (12)

0.035

 Permanent pacemaker

0 (0)

2 (1)

NS

 Gastrointestinal

0

0

NS

Primary End Point

 (RBC > 1000 cc, drainage≥2000 cc, or Revision)

26 (28)

27 (15)

NS

  1. Values are given as mean + SD